ClinicalTrials.gg

Program

SYN023

A development code. Also written as “recombinant anti-rabies human monoclonal antibody injection (SYN023)”.

Its studies are mostly in Rabies, led by 2 companies.

Furthest: phase 3, since Nov 16, 20205 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Synermore Biologics (Suzhou)30 open or runningphase 3since Nov 16, 2020May 10, 2020none ahead
Synermore Biologics20 open or runningphase 2since Nov 1, 2016Nov 1, 2016none ahead

Also a collaborator on its studies: simoon-record-pharma-information-consulting-co-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 1, 2016First study: phase 2 study in Human RabiesNew to Synermore BiologicsSynermore Biologics · NCT02956746 · 164 enrolled · United States
  2. May 16, 2019Phase 2 study in RabiesSynermore Biologics · NCT03961555 · 448 enrolled · United States, Philippines
  3. May 10, 2020Synermore Biologics (Suzhou)'s first study: phase 2 study in ZoonosesNew to Synermore Biologics (Suzhou)Synermore Biologics (Suzhou) · NCT04495569 · 33 enrolled · China
  4. Nov 16, 2020Phase 3 study in RabiesSynermore Biologics (Suzhou) · NCT04644484 · 1,000 enrolled · China
  5. Dec 24, 2025Phase 1 study in RabiesSynermore Biologics (Suzhou) · NCT07342257 · 108 enrolled · China

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 5 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07342257Rabies · China1CompletedSynermore Biologics (Suzhou)May 9, 2025108
NCT04644484Rabies · China3CompletedSynermore Biologics (Suzhou)Jun 24, 20221,000
NCT04495569Zoonoses · China2CompletedSynermore Biologics (Suzhou)Jun 20, 201933
NCT03961555Rabies · United States, Philippines2CompletedSynermore BiologicsDec 23, 2021448
NCT02956746Human Rabies · United States2CompletedSynermore BiologicsDec 2017164

How it is read

Names in the registry

  • “SYN023”, 4 entries
  • “recombinant anti-rabies human monoclonal antibody injection (SYN023)”, 1 entry

Codes read as this program: SYN023.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.